Oral Solid Dosage Contract Manufacturing Market Growth & Trends
The global oral solid dosage contract manufacturing market size is expected to reach USD 54.7 billion by 2030 and expand at a CAGR of 5.97% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing complexity of new drug molecules, R&D investments by large CMOs & CDMOs and rising demand for novel therapies are key factors driving market growth.
Oral solids are widely accepted dosage forms in the pharmaceutical sector since they are cost-effective, simple to manufacture, and patient-friendly. Furthermore, advances in drug delivery technology, such as control release and sustained release formation, are enabling oral solids to achieve even higher levels of bioavailability while lowering drug administration frequency. Thereby, it is anticipated to propel market growth potential.
Technological advancements in the development and bulk manufacturing of oral solid dosage forms are among the primary factors supporting the fast-track commercialization of these products. Currently, a diverse array of dosage forms is accessible in the market. However, the nutraceutical and pharmaceutical industries consistently put effort into developing OSD forms. This preference is due to their ease of handling, convenient consumption, and positive patient adherence. Anticipated advancements in technology and materials of OSD forms are projected to boost the demand for these formulations.
Gather more insights about the market drivers, restrains and growth of the Global Oral Solid Dosage Contract Manufacturing Market
Furthermore, R&D investments by CMOs and CDMOs contribute to enhanced innovation in manufacturing processes, formulation development, & analytical technologies. This can lead to the adoption of more efficient and advanced manufacturing techniques in the production of oral solid dosage forms. Also, investments in R&D result in the expansion of manufacturing capabilities and improved scalability. This allows CMOs and CDMOs to offer larger volumes of oral solid dosage production to meet the increasing demand from pharmaceutical companies.
Moreover, the industry witnessed many strategic movements in 2023, such as collaborations, partnerships, M&As, service expansion, etc.
- In July 2023, Aenova Group and Galvita entered a strategic partnership to improve the formulation, production, and development of oral dosage forms.
- In April 2023, Aenova invested approximately USD 21.96 million (20 million euros) to expand its high-volume solids site in Tittmoning, resulting in increased capacity.
- In January 2023, Catalent and Ethicann collaborated to develop Ethicann’s clinical drug pipeline using Catalent’s technology known as Orally Disintegrating Tablet (ODT) technology.
Browse through Grand View Research's Medical Devices Industry Research Reports.
- Vital Signs Monitoring Devices Market Size, Share & Trends Analysis Report By Product (BP Monitors, Pulse Oximeters), By End-use (Hospitals, Ambulatory Centers), By Region, And Segment Forecasts, 2023 - 2030
- Surgical Microscopes Market Size, Share & Trends Analysis Report By Type (On Casters, Wall Mounted, Tabletop), By Application, By End Use, By Region, And Segment Forecasts, 2024 - 2030
Oral Solid Dosage Contract Manufacturing Market Segmentation
Grand View Research has segmented the global oral solid dosage contract manufacturing market based on product type, mechanism, service, drug potency, prescription type, therapeutic area, end-use, region:
Oral Solid Dosage Contract Manufacturing Product Type Outlook (Revenue, USD Million, 2018 - 2030)
- Tablets
- Capsules
- Powders
- Granules
- Others
Oral Solid Dosage Contract Manufacturing Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
- Immediate Release
- Delayed Release
- Controlled Release
Oral Solid Dosage Contract Manufacturing Service Outlook (Revenue, USD Million, 2018 - 2030)
- Drug Product Development
- Fill Finish Product Manufacturing
- API Manufacturing
- Others
Oral Solid Dosage Contract Manufacturing Drug Potency Outlook (Revenue, USD Million, 2018 - 2030)
- High Potent Drugs
- Moderate Potent Drugs
- Low Potent Drugs
Oral Solid Dosage Contract Manufacturing Prescription Type Outlook (Revenue, USD Million, 2018 - 2030)
- Prescription Drugs
- Over-The-Counter Drugs
Oral Solid Dosage Contract Manufacturing Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
- Oncology
- Cardiovascular Diseases
- Metabolic Disorders
- Neurological Disorders
- infectious Diseases
- Gastrointestinal Diseases
- Other Therapeutic Areas
Oral Solid Dosage Contract Manufacturing End-Use Outlook (Revenue, USD Million, 2018 - 2030)
- Large Size Companies
- Medium & Small Size Companies
- Others
Oral Solid Dosage Contract Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Order a free sample PDF of the Oral Solid Dosage Contract Manufacturing Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research is a full-time market research and consulting company registered in San Francisco, California. The company fully offers market reports, both customized and syndicates, based on intense data analysis. It also offers consulting services to business communities and academic institutions and helps them understand the global and business scenario to a significant extent. The company operates across multitude of domains such as Chemicals, Materials, Food and Beverages, Consumer Goods, Healthcare, and Information Technology to offer consulting services.
Explore Horizon, the world's most expansive market research database
